Tempus AI, Inc. (BCBA:TEM)
Argentina · Delayed Price · Currency is ARS | Market Cap | 14.62T -3.6% |
| Revenue (ttm) | 2.12T +50.4% |
| Net Income | -376.93B |
| EPS | -2,123.99 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,482 |
| Open | 7,020.00 |
| Previous Close | 7,180.00 |
| Day's Range | 6,785.00 - 7,035.00 |
| 52-Week Range | 5,165.00 - 13,350.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Tempus AI added to CellCarta’s CDx commercialization lab network
Tempus AI (TEM) announced a strategic collaboration with CellCarta, a global CRO laboratory supporting the biopharmaceutical industry. Under the agreement, CellCarta will include Tempus in its CDx Com...
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO l...
Personalis says not providing guidance or conducting earnings call
As a result of the announcement on July 20, 2026 that Personalis (PSNL) and Tempus AI (TEM) have entered into an Agreement and Plan of Merger, Personalis will no longer…
Tempus AI announces study results of PRISM2
Tempus AI (TEM) announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft (MSFT), can perform cl...
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating tha...
Tempus AI price target lowered to $56 from $58 at Piper Sandler
Piper Sandler lowered the firm’s price target on Tempus AI (TEM) to $56 from $58 following quarterly results. The firm keeps a Neutral rating on the shares. Published first on…
Tempus AI price target lowered to $70 from $80 at BTIG
BTIG lowered the firm’s price target on Tempus AI (TEM) to $70 from $80 and keeps a Buy rating on the shares following quarterly results. The firm notes Tempus delivered…
Tempus AI price target lowered to $56 from $64 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Tempus AI (TEM) to $56 from $64 and keeps a Buy rating on the shares. The company reported a…
Tempus AI price target lowered to $52 from $64 at BofA
BofA lowered the firm’s price target on Tempus AI (TEM) to $52 from $64 and keeps a Neutral rating on the shares. The firm updated its estimates after the company’s…
Tempus AI price target lowered to $50 from $60 at Stifel
Stifel lowered the firm’s price target on Tempus AI (TEM) to $50 from $60 and keeps a Hold rating on the shares. While the firm trimmed its target after a…
Tempus AI price target lowered to $59 from $67 at Baird
Baird lowered the firm’s price target on Tempus AI (TEM) to $59 from $67 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Tempus AI Earnings Call Transcript: Q2 2026
Q2 revenue grew 22% year-over-year, driven by strong Diagnostics and Data & Apps performance, with major pharma deals and FDA approvals setting up significant future revenue gains. The Personalis acquisition and new financing support continued growth and margin expansion.
Tempus AI Earnings release: Q2 2026
Tempus AI released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Tempus AI Quarterly report: Q2 2026
Tempus AI has published its Q2 2026 quarterly earnings report on July 30, 2026.
Tempus AI Slides: Q2 2026
Tempus AI has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Tempus AI raises FY26 revenue view to $1.595B-$1.605B, consensus $1.59B
Backs FY26 adjusted EBITDA view roughly $65M. Guidance assumes no impact from the Personalis transaction, which is expected to close in late Q4 2026 or early 2027. Published first on…
Tempus AI reports Q2 adjusted EPS (4c), consensus (15c)
Reports Q2 revenue $382.5M, consensus $379.54M. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have…
Tempus Reports Second Quarter 2026 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, ...
Tempus AI announces national launch of OneOme pharmacogenomics testing
Tempus AI (TEM) announced the national launch of its OneOme pharmacogenomics testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. ...
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneO...
Personalis price target raised to $16.25 from $11 at BTIG
BTIG raised the firm’s price target on Personalis (PSNL) to $16.25 from $11 and keeps a Buy rating on the shares after Tempus AI (TEM) said it will acquire Personalis…
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”
Tempus AI ($TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis ($PSNL) in an all-stock deal valued at $1.7 billion. The…
Morgan Stanley sees strategic logic in Personalis deal despite financial hurdles
Morgan Stanley notes that Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25 per share, with the deal expected to close in late 2026 or early…
AI Daily: Tempus AI to acquire Personalis at enterprise value of $1.5B
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly. PERSONALIS…
Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis
The major averages were mixed near noon as stocks look to rebound from last week’s technology-led selloff. Attention is turning to a week of megacap earnings that could determine whether…